Treatment Updates in Ph+ Acute Lymphoblastic Leukemia
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss updates to the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.
EP. 1: Prevalence and Prognosis of Ph+ Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
EP. 2: Current Standards of Care for Ph+ Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss current standards of care for the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
EP. 3: The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL
Elias Jabbour, MD, MD Anderson Cancer Center
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
EP. 4: Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALL
Elias Jabbour, MD, MD Anderson Cancer Center
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
EP. 5: Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.
EP. 6: Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.
